MLTX
MoonLake Immunotherapeutics
NASDAQ · CHHealthcareBiotechnology
$19.05-3.20%
Price as of Jul 20, 2026
MLTX financials
MoonLake Immunotherapeutics financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $2.6M | $0.00 | $0.00 | $0.00 |
| Gross profit | -$2.6M | $0.00 | $0.00 | $0.00 |
| Operating expenses | $242.2M | $143.1M | $54.1M | $65.1M |
| Operating income | -$244.8M | -$143.1M | -$54.1M | -$65.1M |
| Net income | -$227.3M | -$118.9M | -$36.0M | -$50.0M |
| EBITDA | -$219.8M | -$119.6M | -$43.6M | -$64.3M |
| Basic EPS | $-3.53 | $-1.89 | $-0.73 | $-2.20 |
| Diluted EPS | $-3.53 | $-1.89 | $-0.73 | $-2.20 |
| Balance sheet | ||||
| Cash & equivalents | $334.5M | $180.4M | $451.2M | $39.5M |
| Total assets | $424.4M | $477.9M | $526.5M | $76.8M |
| Total liabilities | $120.0M | $24.5M | $13.0M | $8.1M |
| Stockholders’ equity | $304.5M | $446.8M | $495.7M | $48.9M |
| Total debt | $75.7M | $2.8M | $3.7M | $282.6K |
| Net debt | -$258.8M | -$177.6M | -$447.5M | -$39.2M |
| Cash flow | ||||
| Operating cash flow | -$196.0M | -$116.6M | -$42.8M | -$55.9M |
| Capital expenditure | -$35.0K | -$519.5K | -$284.6K | -$16.0K |
| Free cash flow | -$196.0M | -$117.1M | -$43.1M | -$55.9M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | -$50 | $0.00 | $0.00 |